History

06/2014

A novel epigenetic assay for follicular T helper cells (Tfh cells) was validated and is now offered for service testing.

01/2014

Epigenetic assays for Treg and T cells are adapted to allow immune cell monitoring in samples derived from fixed (e.g. paraffin embedded) tissue samples.

12/2013

Epiontis has provided immune cell monitoring for more than 20 clinical trials and has served six out of the twelve largest pharmaceutical companies.

10/2012

An epigenetic assay that monitors Th17 cells was developed and validated. Epiontis now offers a portfolio of 12 immune cell monitoring assays.

09/2012

Novel uses for the Treg assay were demonstrated in five additional publications in the year 2012 by Epiontis and collaborators.

08/2011

The German Accreditation Body attests that Epiontis is competent under the terms of DIN EN ISO/IEC 17025:2005 to carry out tests in medical laboratory testing in studies and clinical monitoring.

03/2011

In the journals Epigenetics and Blood, Epiontis publishes results for novel epigenetic assays that monitor T cells and CCR6 positive cells, respectively. In addition, a novel assay format is developed and presented.

12/2010

Until the end of 2010, Epiontis successfully delivered results to at least 11 pharmaceutical and biotech companies. In addition, more than 20 pilot studies for corporate and academic customers were conducted.

12/2010

Epiontis developed and validated five novel epigenetic assays for immune cells and now offers a portfolio of six immune monitoring assays.

12/2009

Together with collaborators, four additional scientific reports relating to the Treg assay were published in 2009 by Epiontis scientists in renowned journals including Blood, Cancer Research and Journal of European Immunology.

01/2009

Epiontis publishes a key paper further describing the Epiontis Treg Assay and outlining the use of the assay in several indications.

12/2008

Epiontis was awarded a business innovation grant by Zukunftsfonds Berlin for 2.1 mil. Euro over a period of three years, which will be used to broaden Epiontis' development pipeline in collaboration with the Charite Clinic in Berlin.

09/2007

Epiontis publishes results describing the development of the epigenetic Treg Assay, a novel tool to measure suppressive immune cells with fields of use in cancer, autoimmune diseases and immunotherapy.

10/2005 to 06/2007

Epiontis successfully completed a collaboration with Genzyme Corp. for the development of a methylation fingerprint-based assay for the quality control process of Carticel, an autologous chondrocyte cell therapy product.

03/2003

Epiontis was founded by its management team.

1999

Sven Olek, Founder and CEO of Epiontis, co-authors the patent outlining a novel molecular cell identification technology that forms the basis of the intellectual property of Epiontis.  

  1. Privacy Statement: Your phone number or email address will be exclusively used to contact you and will not be given to any third party.